Heiko Schöder
YOU?
Author Swipe
View article: Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials Open
View article: Differential Clearance of [<sup>177</sup>Lu]Lu-PSMA-617 from Metastatic Prostate Cancer Lesions and Normal Tissues creates a Window for Safe Application of DNA Repair Inhibitors
Differential Clearance of [<sup>177</sup>Lu]Lu-PSMA-617 from Metastatic Prostate Cancer Lesions and Normal Tissues creates a Window for Safe Application of DNA Repair Inhibitors Open
Background DNA repair inhibitors may safely enhance targeted radiotherapy if they can be administered when radioisotope has cleared from critical normal tissues. We investigated whether the kinetics of [ 177 Lu]Lu-PSMA-617 (Pluvicto) would…
View article: 18F-BMS-986229 PET imaging of tumor PD-L1 expression in glioblastoma patients
18F-BMS-986229 PET imaging of tumor PD-L1 expression in glioblastoma patients Open
NCT02617589. Trial Registration Date: December 1st, 2015.
View article: Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma Open
View article: Brown adipose tissue machine learning nnU-Net V2 network using TriDFusion (3DF)
Brown adipose tissue machine learning nnU-Net V2 network using TriDFusion (3DF) Open
BACKGROUND: Recent advances in machine learning have revolutionized medical imaging. Currently, identifying brown adipose tissue (BAT) relies on manual identification and segmentation on Fluorine-(18) fluorodeoxyglucose positron emission t…
View article: Delta-like ligand 3 expression and functional imaging in gastroenteropancreatic neuroendocrine neoplasms
Delta-like ligand 3 expression and functional imaging in gastroenteropancreatic neuroendocrine neoplasms Open
Purpose Delta-like ligand 3 (DLL3) is an emerging target across neuroendocrine cancers, but remains underexplored in gastroenteropancreatic neuroendocrine neoplasms (GEP NENs) including poorly differentiated neuroendocrine carcinomas (GEP …
View article: OT06 | AHOD2131: A RANDOMIZED PHASE 3 RESPONSE‐ADAPTED TRIAL COMPARING STANDARD THERAPY TO IMMUNO‐ONCOLOGY FOR CHILDREN & ADULTS WITH NEWLY DIAGNOSED STAGE I/II HODGKIN LYMPHOMA
OT06 | AHOD2131: A RANDOMIZED PHASE 3 RESPONSE‐ADAPTED TRIAL COMPARING STANDARD THERAPY TO IMMUNO‐ONCOLOGY FOR CHILDREN & ADULTS WITH NEWLY DIAGNOSED STAGE I/II HODGKIN LYMPHOMA Open
View article: 233 | S1608: RANDOMIZED PHASE II TRIAL COMPARING LENALIDOMIDE/OBINUTUZUMAB AND UMBRALISIB/OBINUTUZUMAB WITH CHEMOIMMUNOTHERAPY IN EARLY PROGRESSING FOLLICULAR LYMPHOMA (POD24)
233 | S1608: RANDOMIZED PHASE II TRIAL COMPARING LENALIDOMIDE/OBINUTUZUMAB AND UMBRALISIB/OBINUTUZUMAB WITH CHEMOIMMUNOTHERAPY IN EARLY PROGRESSING FOLLICULAR LYMPHOMA (POD24) Open
View article: 373 | PROGNOSTIC VALUE OF 18F‐FDG PET/CT VOLUMETRIC PARAMETERS IN CHILDHOOD, ADOLESCENT, AND YOUNG ADULT HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW FROM THE SEARCH GROUP
373 | PROGNOSTIC VALUE OF 18F‐FDG PET/CT VOLUMETRIC PARAMETERS IN CHILDHOOD, ADOLESCENT, AND YOUNG ADULT HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW FROM THE SEARCH GROUP Open
View article: GPA33-pretargeted radioimmunotherapy with mono- and bivalent DOTA-based Lu-177-labeled radiohaptens in a mouse orthotopic liver xenograft model of metastatic human colorectal cancer
GPA33-pretargeted radioimmunotherapy with mono- and bivalent DOTA-based Lu-177-labeled radiohaptens in a mouse orthotopic liver xenograft model of metastatic human colorectal cancer Open
Rationale: Pretargeted radioimmunotherapy (PRIT), which combines systemic antibody-based targeting with ionizing radiation, is promising for treating liver metastases in patients with colorectal cancer (CRC). Previously, we establis…
View article: CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma
CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma Open
The role of extranodal (EN) sites as potential sanctuary regions resistant to CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy in large B-cell lymphoma (LBCL) remains unclear. To investigate this, we retrospectively analyzed …
View article: An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma Open
View article: Predicting the hypoxic volume of head and neck tumors from fluorodeoxyglucose positron emission tomography images using artificial intelligence
Predicting the hypoxic volume of head and neck tumors from fluorodeoxyglucose positron emission tomography images using artificial intelligence Open
View article: Machine-learning based quantification of lung shunt fraction from 99mTc-MAA SPECT/CT for selective internal radiation therapy of liver tumors using TriDFusion (3DF)
Machine-learning based quantification of lung shunt fraction from 99mTc-MAA SPECT/CT for selective internal radiation therapy of liver tumors using TriDFusion (3DF) Open
View article: Supplementary Figure S2 from Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma
Supplementary Figure S2 from Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma Open
Supplementary Figure S2. Patterns of first failure for RT bridged patients.
View article: Supplementary Table S1 from Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma
Supplementary Table S1 from Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma Open
Supplementary Table S1. Systemic bridging regimens.
View article: Supplementary Figure S1 from Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma
Supplementary Figure S1 from Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma Open
Supplementary Figure S1. Schematic depicting timing of imaging assessment and analytic approach.
View article: Supplementary Table S2 from Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma
Supplementary Table S2 from Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma Open
Supplementary Table S2. Radiation characteristics.
View article: Data from Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma
Data from Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma Open
Purpose:Greater disease burden is a well-established predictor of poorer outcomes following chimeric antigen receptor T-cell (CAR T) therapy. Although bridging therapy (BT) is widely used between leukapheresis and CAR T infusion, limited d…
View article: Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes
Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes Open
Chimeric antigen receptor (CAR) T-cell therapy has transformed the care of lymphoma, yet many patients relapse. Several prognostic markers have been associated with CAR T-cell outcomes, such as tumor burden, response to bridging chemothera…
View article: Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes Open
View article: [18F]TFB PET/CT misses intense [124I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancer
[18F]TFB PET/CT misses intense [124I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancer Open
Background Fluorine 18-labelled tetrafluoroborate ([ 18 F]TFB) is a substrate for the sodium/iodide symporter. In thyroid cancer, [ 18 F]TFB-PET/CT may be an alternative to iodine imaging to evaluate the extent of disease, eligibility for …
View article: Tumor Hypoxia on <sup>18</sup>F-fluoromisonidazole Positron Emission Tomography and Distant Metastasis From Head and Neck Squamous Cell Carcinoma
Tumor Hypoxia on <sup>18</sup>F-fluoromisonidazole Positron Emission Tomography and Distant Metastasis From Head and Neck Squamous Cell Carcinoma Open
Importance Given high rates of locoregional control after definitive management of head and neck squamous cell carcinoma (HNSCC), better methods are needed to project distant metastasis (DM) risk. Tumor hypoxia on 18 F-fluoromisonidazole (…
View article: F18-FDG PET imaging as a diagnostic tool for immune checkpoint inhibitor–associated acute kidney injury
F18-FDG PET imaging as a diagnostic tool for immune checkpoint inhibitor–associated acute kidney injury Open
View article: <i>Erratum</i> to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
<i>Erratum</i> to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation Open
View article: International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline<sup>18</sup>F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation
International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline<sup>18</sup>F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation Open
Total metabolic tumor volume (TMTV) is prognostic in lymphoma. However, cutoff values for risk stratification vary markedly, according to the tumor delineation method used. We aimed to create a standardized TMTV benchmark dataset allowing …
View article: Calibrated CAR Signaling Enables Low-Dose Therapy in Large B-Cell Lymphoma
Calibrated CAR Signaling Enables Low-Dose Therapy in Large B-Cell Lymphoma Open
We designed a CD19-targeted CAR comprising a calibrated signaling module, termed 1XX, that differs from that of conventional CD28/CD3z and 4-1BB/CD3z CARs. Here we report the first-in-human, phase 1 clinical trial of 19(T2)28z-1XX CAR T ce…
View article: Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma
Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma Open
Relapse and toxicity limit the effectiveness of chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL), yet biomarkers that predict outcomes and toxicity are lacking. We examined radiomic features extracted from …
View article: <sup>18</sup>F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer
<sup>18</sup>F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer Open
Anti-programmed death 1 (PD-1) inhibitors are the standard of care for advanced gastroesophageal cancer. Although recommendations and approval by regulatory agencies are often based on programmed death ligand 1 (PD-L1) expression, patholog…
View article: Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis
Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis Open
Several single-arm studies have explored the inclusion of brentuximab vedotin (BV) in salvage chemotherapy followed by autologous stem cell transplantation (ASCT) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, no …